2. Academic Validation
  3. In vivo efficacy of apramycin in murine infection models

In vivo efficacy of apramycin in murine infection models

  • Antimicrob Agents Chemother. 2014 Nov;58(11):6938-41. doi: 10.1128/AAC.03239-14.
Martin Meyer 1,  Pietro Freihofer 1,  Michael Scherman 2,  Joanne Teague 3,  Anne Lenaerts 2,  Erik C Böttger 4
Affiliations

Affiliations

  • 1 Institut für Medizinische Mikrobiologie, Nationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland.
  • 2 Mycobacterial Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado, USA.
  • 3 Euprotec Limited, Manchester, United Kingdom.
  • 4 Institut für Medizinische Mikrobiologie, Nationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland boettger@imm.uzh.ch.
PMID: 25136009 DOI: 10.1128/AAC.03239-14
Abstract

Apramycin is a unique Aminoglycoside with a dissociation of Antibacterial activity and ototoxicity. We assessed the Antibacterial efficacy of apramycin in two murine models of Infection, Mycobacterium tuberculosis aerosol Infection and Staphylococcus aureus septicemia. In both Infection models, the efficacy of apramycin was comparable to that of amikacin. These results suggest that apramycin has the potential to become a clinically useful agent against drug-resistant pathogens and support further development of this promising unique Aminoglycoside.

Figures
Products